6 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Terminated 6 |
| Phase 2 | 3 | Terminated 3 |
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia Binocular video games, Patching of the sound eye - Amblyopia | Phase 1 | Terminated | Novartis Pharmaceuticals | 27 | 2021-06-30 | 2023-05-23 |
| Extension Study to Study PQ-110-001 (NCT03140969) QR-110 - Leber Congenital Amaurosis 10, Blindness | Phase 1 / Phase 2 | Terminated | Laboratoires Thea | 9 | 2019-05-13 | 2024-10-15 |
| BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES BIIB092, Placebo - Primary Tauopathies, Corticobasal Degeneration Syndrome | Phase 1 | Terminated | University of California, San Francisco | 22 | 2018-09-12 | 2019-12-19 |
| Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene AAV2/5-hPDE6B - Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | eyeDNA Therapeutics | 19 | 2017-11-06 | 2025-12-18 |
| Dichoptic Virtual Reality Therapy for Amblyopia in Adults Dichoptic therapy, Patching therapy, Dioptic (non-dichoptic) therapy - Amblyopia, Anisometropia | Phase 1 | Terminated | University of California, San Francisco | 17 | 2014-10-01 | 2017-05-03 |
| Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B SAR421869 - Usher Syndrome, Retinitis Pigmentosa | Phase 1 / Phase 2 | Terminated | Sanofi | 9 | 2012-03-26 | 2022-04-28 |
Eye Diseases (3) · Amblyopia (2) · Eye Diseases, Hereditary (2) · Retinal Diseases (2) · Retinitis Pigmentosa (2) · Anisometropia (1) · Blindness (1) · Color Vision Defects (1) · Eye Abnormalities (1) · Leber Congenital Amaurosis (1) · Leber Congenital Amaurosis 10 (1) · Meckel Syndrome, Type 4 (1) · Neurologic Manifestations (1) · Optic Atrophy, Hereditary, Leber (1)
Nervous System Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Neurologic Manifestations (5) · Sensation Disorders (5) · Brain Diseases (3) · Central Nervous System Diseases (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Eye Diseases (3) · Genetic Diseases, Inborn (3) · Congenital Abnormalities (2) · Cranial Nerve Diseases (2) · Eye Diseases, Hereditary (2) · Metabolic Diseases (2)
Therapeutics (1) · gosuranemab (1)
University of California, San Francisco (2) · Laboratoires Thea (1) · Novartis Pharmaceuticals (1) · Sanofi (1) · eyeDNA Therapeutics (1)
United States (5) · France (2) · Australia (1) · Belgium (1) · Canada (1)
Adam Boxer, MD, PhD (1) · Jose-Alain Sahel, MD, PhD (1) · Richard Weleber, MD (1)
PMID 22828504, PMID 24705452, PMID 26857842, PMID 30646425
2016 (1), 2018 (1)